About Keratin, type I cuticular Ha2
Keratin, type I cuticular Ha2 (KRT32) is a protein
from Homo sapiens identified by UniProt accession
Q14532, 448 residues long.
MolForge cross-references it against 0 known binders and
45 disease associations.
Target properties
| Protein name | Keratin, type I cuticular Ha2 |
| UniProt accession | Q14532 |
| Gene | KRT32 |
| Organism | Homo sapiens |
| Length | 448 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (45)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.19
- head and neck squamous cell carcinoma · score 0.18
- ovarian cancer · score 0.18
- breast adenocarcinoma · score 0.18
- thyroid gland adenocarcinoma · score 0.16
- esophageal cancer · score 0.14
- hair shape measurement · score 0.09
- hemoglobin E-beta-thalassemia syndrome · score 0.05
- hemoglobin D disease · score 0.05
- familial pityriasis rubra pilaris · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14532-F1 | alphafold | PREDICTED | 75.22 | — |
Amino-acid sequence (448 residues)
MTSSCCVTNN LQASLKSCPR PASVCSSGVN CRPELCLGYV CQPMACLPSV CLPTTFRPAS CLSKTYLSSS CQAASGISGS MGPGSWYSEG AFNGNEKETM QFLNDRLASY LTRVRQLEQE NAELESRIQE ASHSQVLTMT PDYQSHFRTI EELQQKILCT KAENARMVVN IDNAKLAADD FRAKYEAELA MRQLVEADIN GLRRILDDLT LCKADLEAQV ESLKEELMCL KKNHEEEVGS LRCQLGDRLN IEVDAAPPVD LTRVLEEMRC QYEAMVEANR RDVEEWFNMQ MEELNQQVAT SSEQLQNYQS DIIDLRRTVN TLEIELQAQH SLRDSLENTL TESEARYSSQ LAQMQCMITN VEAQLAEIRA DLERQNQEYQ VLLDVRARLE GEINTYRSLL ENEDCKLPCN PCSTPSCTTC VPSPCVPRTV CVPRTVGMPC SPCPQGRY
Explore Keratin, type I cuticular Ha2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets